Gaush Meditech Ltd logo

Gaush Meditech Ltd

2407.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$4.69

+HK$0.29 · +6.59%

Aug 24, 4:08 PM HKT

2407.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Xinwei Liu
Listed since
Dec 12, 2022
Employees
893

Market position

Day range

Current HK$4.69

52-week range

Current HK$4.69

Open
HK$4.49
Previous close
HK$4.40
Volume
32.3K
0.65× average
Average volume
49.77K
Average daily volume
Market cap
693.59M HKD
Beta
0
Market reference 1
50-day average
HK$4.9484
-5.22% below average
200-day average
HK$6.2699
-25.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.14B CNY
P/E (TTM)
6.09×
P/B (TTM)
0.34×
P/S (TTM)
0.43×
EV / EBITDA
6.72×
Earnings yield
8.96%
Free cash flow yield
10.29%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
45.87%
Operating margin
8.81%
Net margin
6.97%
Return on equity
5.70%
Return on assets
3.66%
Return on invested capital
4.16%

Financial health

Debt / equity
0.3×
Current ratio
2.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%27%-5%-36%Gross margin, FY2021: 46.95%Gross margin, FY2022: 49.88%Gross margin, FY2023: 49.18%Gross margin, FY2024: 46.44%Gross margin, FY2025: 45.87%Operating margin, FY2021: 19.81%Operating margin, FY2022: 19.64%Operating margin, FY2023: 19.85%Operating margin, FY2024: 13.80%Operating margin, FY2025: 8.81%Net margin, FY2021: -14.67%Net margin, FY2022: -27.89%Net margin, FY2023: 12.34%Net margin, FY2024: 6.47%Net margin, FY2025: 6.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.95%. Gross margin FY2022 49.88%. Gross margin FY2023 49.18%. Gross margin FY2024 46.44%. Gross margin FY2025 45.87%. Operating margin FY2021 19.81%. Operating margin FY2022 19.64%. Operating margin FY2023 19.85%. Operating margin FY2024 13.80%. Operating margin FY2025 8.81%. Net margin FY2021 -14.67%. Net margin FY2022 -27.89%. Net margin FY2023 12.34%. Net margin FY2024 6.47%. Net margin FY2025 6.97%.

Income trends

Revenue

1.38B CNY-3.36%

Operating income

121.65M CNY-38.31%

Net income

96.19M CNY+4.11%
Income trends across reported periods1.61B CNY894.99M CNY183.79M CNY−527.42M CNYRevenue, FY2021: 1.3B CNYRevenue, FY2022: 1.25B CNYRevenue, FY2023: 1.41B CNYRevenue, FY2024: 1.43B CNYRevenue, FY2025: 1.38B CNYOperating income, FY2021: 257.12M CNYOperating income, FY2022: 246.22M CNYOperating income, FY2023: 279.16M CNYOperating income, FY2024: 197.19M CNYOperating income, FY2025: 121.65M CNYNet income, FY2021: −190.45M CNYNet income, FY2022: −349.62M CNYNet income, FY2023: 173.52M CNYNet income, FY2024: 92.39M CNYNet income, FY2025: 96.19M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.3B CNY. Revenue FY2022 1.25B CNY. Revenue FY2023 1.41B CNY. Revenue FY2024 1.43B CNY. Revenue FY2025 1.38B CNY. Operating income FY2021 257.12M CNY. Operating income FY2022 246.22M CNY. Operating income FY2023 279.16M CNY. Operating income FY2024 197.19M CNY. Operating income FY2025 121.65M CNY. Net income FY2021 −190.45M CNY. Net income FY2022 −349.62M CNY. Net income FY2023 173.52M CNY. Net income FY2024 92.39M CNY. Net income FY2025 96.19M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue1.38B CNY1.43B CNY1.41B CNY1.25B CNY1.3B CNY
Cost of goods sold747.16M CNY765.01M CNY714.64M CNY628.45M CNY688.75M CNY
Gross profit633.2M CNY663.39M CNY691.6M CNY625.34M CNY609.47M CNY
Research and development92.58M CNY78.42M CNY52.88M CNY41.09M CNY23.51M CNY
Selling, general, and administrative418.98M CNY378.36M CNY378.21M CNY333.94M CNY320.99M CNY
Operating expenses511.55M CNY437.37M CNY412.45M CNY360.53M CNY330.59M CNY
Interest income2.46M CNY3.18M CNY6.58M CNY4.68M CNY2.02M CNY
Interest expense19.59M CNY36.71M CNY50.61M CNY42.68M CNY83.53M CNY
Depreciation and amortization57.1M CNY52.76M CNY75.97M CNY44.87M CNY43.88M CNY
Operating income121.65M CNY197.19M CNY279.16M CNY246.22M CNY257.12M CNY
Net income96.19M CNY92.39M CNY173.52M CNY−349.62M CNY−190.45M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.45

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates1.15-0.49-2.12-3.75Q4 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Q4 2022, reported Nov 20, 2022: actual -0.714, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual -3.42, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 24, 2023: actual 0.81, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 25, 2024: actual 0.465, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 0.204, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 0.468, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 0.285, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 26, 2026: actual 0.445, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates869.99M794.34M718.69M643.03MQ4 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Q4 2022, reported Nov 20, 2022: actual 676.49M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual 769.8M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 24, 2023: actual 757.22M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 25, 2024: actual 780.89M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 689.82M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 836.53M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 715.65M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 26, 2026: actual 809.09M HKD, estimate —, surprise —, Comparison unavailable.

2407.HK peers

ETFs holding 2407.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 2407.HK

research.disclaimer